ArticleFrontiers in pediatrics2026
Epilepsia partialis continua may be a rare electroclinical feature of anti-Hu encephalitis: a pediatric case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paraneoplastic neurologic syndromes with anti-Hu antibodies refer to a spectrum of neurologic disorders. Rare cases of extra-limbic encephalitis presenting with seizures have also been reported. However, these seizures rarely manifest as epilepsia partialis continua (EPC). We report an anti-Hu encephalitis pediatric case with EPC. Case description: A 3-year-and-4-month-old male presented with EPC after neuroblastoma resection for 6 months. Neuronal antibody testing revealed highly positive anti-Hu antibody in both serum and cerebrospinal fluid. Anti-Hu encephalitis with EPC was diagnosed. Initial immunotherapy including intravenous immunoglobulin and methylprednisolone had a transient effect, and the symptom recurred 1 month later. The EPC still existed even with the treatment of prednisone, mycophenolate mofetil, oxcarbazepine, valproic acid, and clonazepam. Conclusion: EPC may be a rare but underrecognized electroclinical feature of anti-Hu encephalitis. It is important to consider anti-Hu encephalitis in patients presenting with new-onset EPC. The heterogeneity in clinical symptoms, EEG and imaging manifestations may indicate the existence of complex and diverse mechanisms. The prognosis of this disease is speculated to be poor. Antiseizure medications and surgery often fail to control the progression of the disease. Immunotherapy may benefit some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.